Roche Holding AG (ROP) - Total Liabilities

Latest as of December 2025: CHF62.82 Billion CHF

Based on the latest financial reports, Roche Holding AG (ROP) has total liabilities worth CHF62.82 Billion CHF as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Roche Holding AG - Total Liabilities Trend (1998–2025)

This chart illustrates how Roche Holding AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Roche Holding AG Competitors by Total Liabilities

The table below lists competitors of Roche Holding AG ranked by their total liabilities.

Company Country Total Liabilities
G2EV34
SA:G2EV34
Brazil R$51.84 Billion
Raytheon Technologies Corp
NYSE:RTX
USA $103.94 Billion
Kweichow Moutai Co Ltd
SHG:600519
China CN¥39.03 Billion
UnitedHealth Group Incorporated
NYSE:UNH
USA $207.88 Billion
Wells Fargo & Company
NYSE:WFC
USA $1.97 Trillion
Philip Morris International Inc
NYSE:PM
USA $77.21 Billion
Westpac Banking Corporation
AU:WBCPI
Australia AU$1.03 Trillion

Liability Composition Analysis (1998–2025)

This chart breaks down Roche Holding AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.38 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.86 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.62 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Roche Holding AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Roche Holding AG (1998–2025)

The table below shows the annual total liabilities of Roche Holding AG from 1998 to 2025.

Year Total Liabilities Change
2025-12-31 CHF62.82 Billion -4.29%
2024-12-31 CHF65.64 Billion +14.75%
2023-12-31 CHF57.20 Billion +1.90%
2022-12-31 CHF56.14 Billion -12.25%
2021-12-31 CHF63.97 Billion +37.97%
2020-12-31 CHF46.37 Billion -1.82%
2019-12-31 CHF47.22 Billion -1.93%
2018-12-31 CHF48.15 Billion +1.01%
2017-12-31 CHF47.67 Billion -5.45%
2016-12-31 CHF50.42 Billion -3.90%
2015-12-31 CHF52.46 Billion -2.81%
2014-12-31 CHF53.98 Billion +31.90%
2013-12-31 CHF40.93 Billion -14.87%
2012-12-31 CHF48.08 Billion +2.09%
2011-12-31 CHF47.09 Billion -4.59%
2010-12-31 CHF49.36 Billion -24.24%
2009-12-31 CHF65.15 Billion +192.59%
2008-12-31 CHF22.27 Billion -10.49%
2007-12-31 CHF24.88 Billion -9.87%
2006-12-31 CHF27.60 Billion -0.08%
2005-12-31 CHF27.62 Billion +11.46%
2004-12-31 CHF24.78 Billion -18.27%
2003-12-31 CHF30.32 Billion -20.67%
2002-12-31 CHF38.22 Billion -7.72%
2001-12-31 CHF41.42 Billion +10.45%
2000-12-31 CHF37.50 Billion -7.25%
1999-12-31 CHF40.43 Billion +22.28%
1998-12-31 CHF33.06 Billion --

About Roche Holding AG

SW:ROP Switzerland Drug Manufacturers - General
Market Cap
$278.72 Billion
CHF220.46 Billion CHF
Market Cap Rank
#64 Global
#1 in Switzerland
Share Price
CHF320.00
Change (1 day)
+2.07%
52-Week Range
CHF300.90 - CHF323.90
All Time High
CHF323.90
About

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more